Want to see SE:GABA full AI Analyst Report?
GABA Stock Chart & Stats
kr0.04
>-kr0.01(-12.89%)
At close: 4:00 PM EST
kr0.04
>-kr0.01(-12.89%)
Day’s Range― - ―
52-Week Rangekr0.02 - kr0.10
Previous CloseN/A
Volume42.79K
Average Volume (3M)2.50M
Market Cap
kr16.36M
Enterprise Valuekr18.78
Total Cash (Recent Filing)kr3.69M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Nov 27, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding610,491,300
10 Day Avg. Volume1,299,769
30 Day Avg. Volume2,495,546
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-6.10
Price to Sales (P/S)0.00
P/FCF Ratio-0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of reported debt reduces interest expense and refinancing exposure, giving Gabather greater financial flexibility than a similarly loss-making biotech with leverage. This supports continued research investment without debt-service obligations, although equity funding remains important.
Improving Loss And Cash-Burn TrendAlthough cash generation remains negative, the improvement from substantially heavier historical losses and burn indicates some progress in cost control or operating efficiency. If sustained, this trend could extend the company’s funding runway and reduce the scale of future financing needs.
Focused CNS Drug DevelopmentGabather has a clearly defined scientific focus on GABA-A receptor programs and central nervous system disorders, rather than an unfocused research agenda. Concentrating resources around one therapeutic system may support deeper expertise and more coherent development priorities over time.
Bears Say
No Revenue Or Commercial BaseZero revenue means the company has not yet demonstrated commercial demand or an operating sales base to support its research activities. Until a candidate reaches commercialization or produces partnership income, future progress remains dependent on development milestones rather than recurring business revenue.
Persistent Cash ConsumptionContinued negative operating and free cash flow shows that Gabather consumes significant cash while generating no revenue inflows. This creates an ongoing need for external financing to sustain operations, leaving the development program exposed to funding requirements over the coming quarters.
Thin And Historically Eroded EquityPeriods of negative equity indicate that historical losses have materially eroded the capital base. Although TTM equity is positive, its modest level relative to continuing losses provides limited balance-sheet resilience and increases the importance of successful fundraising or future operating progress.
GABA FAQ
What was Gabather AB’s price range in the past 12 months?
Gabather AB lowest stock price was kr0.02 and its highest was kr0.10 in the past 12 months.
What is Gabather AB’s market cap?
Gabather AB’s market cap is kr16.36M.
When is Gabather AB’s upcoming earnings report date?
Gabather AB’s upcoming earnings report date is Nov 27, 2026 which is in 68 days.
How were Gabather AB’s earnings last quarter?
Gabather AB released its earnings results on Aug 31, 2026. The company reported kr0 earnings per share for the quarter.
Is Gabather AB overvalued?
According to Wall Street analysts Gabather AB’s price is currently Overvalued.
Does Gabather AB pay dividends?
Gabather AB does not currently pay dividends.
What is Gabather AB’s EPS estimate?
Gabather AB’s EPS estimate is 0.
How many shares outstanding does Gabather AB have?
Gabather AB has 610,491,300 shares outstanding.
What happened to Gabather AB’s price movement after its last earnings report?
Gabather AB reported an EPS of kr0 in its last earnings report. Following the earnings report the stock price went up 5.882%.
Which hedge fund is a major shareholder of Gabather AB?
Currently, no hedge funds are holding shares in SE:GABA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gabather AB
Gabather AB (publ) is dedicated to creating innovative pharmaceutical solutions for a range of central nervous system disorders. The company's focus includes developing medications for conditions such as psychotic illnesses, mood and anxiety disorders, pain relief, and cognitive function enhancement, notably those related to Alzheimer's disease. Founded in 2014, its operations are headquartered in Södertälje, Sweden.